Published in Mol Ther on June 23, 2014
Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles. Int J Nanomedicine (2016) 0.78
Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation. Oncogene (2015) 0.78
An Apta-Biosensor for Colon Cancer Diagnostics. Sensors (Basel) (2015) 0.78
An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.77
Aptamers: A promising chemical antibody for cancer therapy. Oncotarget (2016) 0.77
Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo. Int J Nanomedicine (2014) 0.77
Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget (2016) 0.76
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects. Biomedicines (2017) 0.76
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal (2017) 0.75
Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. Sci Rep (2017) 0.75
Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget (2016) 0.75
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. Sci Rep (2016) 0.75
Structural computational modeling of RNA aptamers. Methods (2016) 0.75
A theranostic "SMART" aptamer for targeted therapy of prostate cancer. Mol Ther (2014) 0.75
Improved Synthesis and In Vitro Evaluation of an Aptamer Ribosomal Toxin Conjugate. Nucleic Acid Ther (2016) 0.75
In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs. Methods (2016) 0.75
Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. Mol Ther (2016) 0.75
Development of a Single Stranded DNA Aptamer as a Molecular Probe for LNCap Cells Using Cell-SELEX. Avicenna J Med Biotechnol (2016) 0.75
Clonogenic assay of cells in vitro. Nat Protoc (2006) 11.85
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer (2005) 5.57
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell (1994) 4.50
Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today (2006) 4.35
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem (2004) 3.49
Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt (2007) 3.04
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Progress towards in vivo use of siRNAs. Mol Ther (2006) 2.56
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
siRNA and innate immunity. Oligonucleotides (2009) 2.28
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature (2010) 1.73
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70
Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis (2006) 1.64
Therapeutic applications of DNA and RNA aptamers. Oligonucleotides (2009) 1.59
Antibody-drug conjugates targeting prostate-specific membrane antigen. Front Biosci (Landmark Ed) (2014) 1.52
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol (2006) 1.48
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest (2011) 1.46
Mechanism of ribose 2'-group discrimination by an RNA polymerase. Biochemistry (1997) 1.32
Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets (2009) 1.19
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer (2003) 1.10
Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv (2013) 1.09
Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate (2000) 1.07
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res (2008) 1.07
Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem (2009) 1.05
The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol (2011) 1.04
New-generation platinum agents for solid tumors. Future Oncol (2009) 0.99
Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem (2011) 0.98
Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol (2012) 0.97
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging (2010) 0.96
Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther Deliv (2012) 0.94
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev (2013) 0.91
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. Expert Opin Investig Drugs (2014) 0.89
Advances and perspectives in cell-specific aptamers. Curr Pharm Des (2011) 0.88
In vivo imaging of the systemic delivery of small interfering RNA. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.82
The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program. Proc West Pharmacol Soc (2009) 0.80
Measurement of glutamate carboxypeptidase II (NAALADase) enzyme activity by the hydrolysis of [³H]-N-acetylaspartylglutamate (NAAG). Curr Protoc Pharmacol (2002) 0.79
Prostate-specific membrane antigen and its truncated form PSM'. Prostate (2009) 0.79
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther (2014) 1.03
The nsp3 macrodomain promotes virulence in mice with coronavirus-induced encephalitis. J Virol (2014) 0.89
Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol (2014) 0.89
Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. Mol Ther (2016) 0.75
Computed Tomography and Magnetic Resonance Imaging for Longitudinal Characterization of Lung Structure Changes in a Yucatan Miniature Pig Silicosis Model. Toxicol Pathol (2016) 0.75
Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. Mol Ther (2016) 0.75